Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics, Inc. (STOK) is a clinical-stage biotechnology leader pioneering RNA-based medicines to address the root causes of severe genetic diseases. This page serves as the definitive source for official updates on therapeutic advancements, financial developments, and strategic initiatives related to their TANGO platform technology.
Investors and researchers will find curated press releases covering clinical trial progress, regulatory milestones, and peer-reviewed research on antisense oligonucleotide therapies. The repository includes updates on STOK's pipeline targeting central nervous system disorders and ocular conditions caused by haploinsufficiency.
Key content categories include treatment development timelines, partnership announcements with academic institutions, and financial performance reports. All materials maintain rigorous scientific accuracy while remaining accessible to both professional analysts and engaged public stakeholders.
Bookmark this page for direct access to Stoke Therapeutics' latest breakthroughs in RNA splicing modulation and protein restoration therapies. Regularly updated to reflect new developments in precision medicine innovation.
Stoke Therapeutics (Nasdaq: STOK) has received authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial (OSPREY) for STK-002, targeting autosomal dominant optic atrophy (ADOA), a rare inherited optic nerve disorder causing vision loss. The study aims to assess the safety and efficacy of STK-002, designed to upregulate OPA1 protein expression and potentially halt vision deterioration. Enrollment for the trial is expected to begin in early 2024. Currently, there are no approved treatments for ADOA, affecting approximately 1 in 30,000 people globally. Stoke's approach leverages the TANGO platform, focusing on treating haploinsufficiencies and CNS diseases.
Stoke Therapeutics (NASDAQ: STOK) announced that the FDA has approved a higher single dose of STK-001 (70mg) for the Phase 1/2a MONARCH study targeting children and adolescents with Dravet syndrome. This study, which aims to evaluate the safety and efficacy of STK-001, complements ongoing assessments in the ADMIRAL trial. Dravet syndrome is a severe genetic epilepsy affecting quality of life, with current treatments inadequate for most patients. Data from the new dose cohort is expected to be released in the second half of 2023, with the company aiming for a Phase 3 trial initiation in 2024.
Stoke Therapeutics (Nasdaq: STOK) announced progress in its STK-001 trials for Dravet syndrome, expecting to complete Phase 1/2a studies in 2023 and initiate Phase 3 in 2024. The company will deliver safety and efficacy data from various dosing cohorts throughout 2023. Financially, Stoke reported revenue of $12.4 million for 2022, a net loss of $101.1 million, and increased R&D expenses totaling $77.8 million. Stoke's cash reserves stand at $230.2 million, projected to fund operations until the end of 2025, supporting the advancement of STK-001 and STK-002.
FAQ
What is the current stock price of Stoke Therapeutics (STOK)?
What is the market cap of Stoke Therapeutics (STOK)?
